Skip to content

ORCHARD THERAPEUTICS PLC

CIK 0001748907

← back to feed
Revenue (TTM)
$20.63M
+1,252.5% YoY Q3 Nov 2023
Net Income (TTM)
−$112.6M
−4.2% YoY Q3 Nov 2023
EPS Diluted (TTM)
−$0.71
−0.9% YoY Q3 Nov 2023
Gross Margin
71.2%
Q3 Nov 2023
Operating Margin
-464.8%
Q3 Nov 2023
Net Margin
-545.8%
Q3 Nov 2023
Free Cash Flow (TTM)
−$140.83M
Q3 Nov 2023
Cash
$23.47M
Q3 Nov 2023
Total Debt
$25.59M
Q3 Nov 2023
Shares Outstanding
227.61M sh
Q3 Nov 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings